COYA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
234.1K
-3.9%
243.7K
-2.9%
251.1K
-93.7%
4.0M
+11.1%
3.6M
Cost of Revenue
0
0
0
0
0
Gross Profit
234.1K
-3.9%
243.7K
-2.9%
251.1K
-93.7%
4.0M
+11.1%
3.6M
Operating Expenses
11.2M
+53.4%
7.3M
-7.6%
7.9M
-21.0%
10.0M
+66.6%
6.0M
R&D
8.6M
+70.8%
5.0M
+22.5%
4.1M
-38.8%
6.7M
+95.6%
3.4M
SG&A
2.6M
+14.6%
2.3M
-40.4%
3.8M
+15.7%
3.3M
+27.9%
2.6M
Operating Income
-10948601
-55.4%
-7046988
+7.8%
-7640217
-26.7%
-6030888
-147.9%
-2432897
EBITDA
-10945794
-55.4%
-7044181
+7.8%
-7637410
-26.8%
-6024047
-148.3%
-2426057
Net Income
-10617741
-59.9%
-6638260
+7.9%
-7206990
-26.2%
-5708542
-169.8%
-2115831
EPS (Basic)
$-0.45
-60.7%
$-0.28
+12.5%
$-0.32
+5.9%
$-0.34
-161.5%
$-0.13
EPS (Diluted)
$-0.45
-60.7%
$-0.28
+12.5%
$-0.32
+5.9%
$-0.34
-161.5%
$-0.13
Shares (Diluted)
23.5M
+0.0%
23.5M
+3.6%
22.6M
+35.2%
16.7M
+0.1%
16.7M
Coya Therapeutics (COYA) — Financials